Author

Pablo Rodríguez-Ramos

Consejo Superior de Investigaciones CientíficasORCID 0000-0002-3766-1406Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Andrea Olarte-San JuaniD· 2 shared Eugenio SantosiD· 2 shared Nuria CalzadaiD· 2 shared Rósula García‐NavasiD· 2 shared Alba Díaz-Aguilera· 1 shared Alberto Fernández‐MedardeiD· 1 shared Barbara MairiD· 1 shared Carmela GómeziD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

Andrea Olarte-San JuanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cell BiologyCell Death and DiseasePeer-reviewedAug 12, 2026

Concomitant ablation of SOS1 and SOS2 triggers a lethal phenotype involving compromised intestinal integrity and widespread septicemia

Andrea Olarte-San Juan, Pablo Rodríguez-Ramos, Alba Díaz-Aguilera…·Rósula García‐Navas

This study shows that deleting both SOS1 and SOS2 in mice causes intestinal damage, bacterial leakage, and septicemia, but stemness-enhancing therapies improve survival.

DOI 10.1038/s41419-026-09185-z

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologyProceedings of the National Academy of SciencesPeer-reviewedMar 12, 2025

Pharmacological SOS1 inhibitor BI-3406 demonstrates in vivo anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumors

Fernando C. Baltanás, Maximilian Kramer‐Drauberg, Rósula García‐Navas…·Eugenio Santos

This study shows that the SOS1 inhibitor BI-3406 effectively reduces tumor growth in KRAS mutant cancers, similar to genetic SOS1 ablation, with comparable efficacy to another KRAS inhibitor.

16 citationstop 5%

mouseproteomics

𝕏 PostBluesky